# Lisata Therapeutics

Source: https://onco.cc/companies/lisata/  
OnCo record `lisata` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lisata is a New Jersey biotech developing certepetide, a peptide that opens up the dense stroma of pancreatic tumours so chemotherapy can reach the cancer cells; it is tested with gemcitabine and nab-paclitaxel.

## Summary

Lisata Therapeutics, formed when Caladrius Biosciences merged with Cend Therapeutics in 2022 and based in Basking Ridge, New Jersey, develops certepetide (LSTA1, formerly CEND-1), a cyclic peptide that binds alpha-v integrins and neuropilin-1 to increase drug penetration into solid tumours. It is tested in metastatic pancreatic cancer with standard chemotherapy and in other stroma-rich tumours, registered on ClinicalTrials.gov under Lisata as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Lisata Therapeutics, Inc.; Caladrius Biosciences; Cend Therapeutics
- Tags: ctgov-sponsor
- HQ: Basking Ridge, NJ
- Type: biotech
- Website: https://www.lisata.com

## Sources

- Official website: https://www.lisata.com
- ClinicalTrials.gov: trials led by Lisata Therapeutics, Inc.: https://clinicaltrials.gov/search?lead=Lisata%20Therapeutics%2C%20Inc.

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/lisata.json